Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Beginners might feel intimidated when it comes to selecting an appropriate handgun, but with a calculated approach, you can find one that fits your budget and fulfills your needs. There are two ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug ...